Researchers to Present Key Findings Regarding the Expanding Role and Clinical Utility of PEM at the RSNA Conference

Mon Nov 19, 2012 8:00am EST

* Reuters is not responsible for the content in this press release.

  SAN DIEGO, CA, Nov 19 (Marketwire) -- 
Researchers will present data in three separate presentations on
molecular breast imaging. Some of these presentations will highlight the
utility and performance of Naviscan's high-resolution organ-specific PET
scanner for the detection of breast cancer at the Radiological Society of
North America (RSNA) 98th Scientific Assembly and Annual Meeting held
November 25 - 30, 2012 in Chicago, Illinois. The presentations will take
place Sunday, November 25 in Room S505AB beginning at 11:25 a.m. The
breast application of the scanner is commonly known as Positron Emission
Mammography or PEM.

    Kirti Kulharni, MD, The University of Chicago, will present The Role of
Positron Emission Mammography (PEM) in Assessing Axillary Lymph Nodes in
Patients with Breast Cancer at 11:25 a.m. - 11:35 a.m. The pilot study
showed that PEM has a 98% specificity for the detection of breast cancer
loco-regional spread to axillary lymph nodes. The authors conclude that
due to this unprecedented specificity, patients with axilla abnormal on
PEM could skip sentinel lymph node procedures and the surgeons could
assume they have lymph node metastasis. 

    Wendie A. Berg, MD, PhD, University of Pittsburgh School of Medicine,
will present Positron Emission Mammography and Molecular Breast Imaging
at 2:00 p.m. - 3:30 p.m. Dr. Berg summarizes the currently approved uses
of PEM in this interactive session. Presented uses include local staging,
evaluation of the response to primary chemotherapy, and the evaluation
for possible cancer recurrence. In addition, exciting areas for future
research in high-resolution radionuclide breast imaging will be discussed.

    Amy Lynn Conners, MD, Mayo Clinic, will present Breast MR Imaging:
Algorithms in Breast Imaging Using BSGI/PEM and MRI Imaging during the
2:00 p.m. - 3:30 p.m. presentation. In this interactive session, Dr.
Conners reviews the strengths and weaknesses of breast MR, breast
specific gamma imaging (BSGI/MBI) and positron emission mammography
(PEM/3D MBI) in the diagnostic and screening settings.

    "We value the scientific contributions of these esteemed researchers,"
stated Paul J. Mirabella, CEO, Naviscan, Inc. "Their ongoing clinical
research, publication of the data and mentoring is further proving the
clinical utility of PEM and expanding its use among clinicians and
patients."

    About Naviscan, Inc.
 Naviscan, founded in 1995, develops and markets
compact, high-resolution PET scanners intended to provide organ-specific
molecular imaging and guide radiological and surgical procedures. The
Naviscan PET scanner is currently installed and available in breast and
imaging centers throughout the world with global distribution in 34
countries. The Company is headquartered in San Diego, California and is
the first to obtain FDA-clearance and CE Mark for a high-resolution PET
scanner designed to image small body parts and for breast biopsy image
guidance. For more information, visit www.naviscan.com.

    
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2157771

Embedded Video Available:
http://www2.marketwire.com/mw/frame_mw?attachid=2157777


Contact Information
Joleen Schultz
Naviscan Marketing Communications 
321 Medical Launch
Tel: +1.858.455.5500
jschultz@naviscan.com 

Copyright 2012, Marketwire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.